Explore more price target data and ratings for Zimmer Biomet Holdings, Inc. on the Forecasts tab, and track all previous and future analyst recommendations for Zimmer Biomet Holdings, Inc. in the dedicated News Flow.Select reference data provided by FactSet. Copyright © 2026 FactSet Research System…
Second quarter sales grew 4.8% reported and 4% organically, led by strong U.S. hip, S.E.T., and technology performance. Guidance for full-year revenue and adjusted EPS was raised, with robust cash flow and continued investment in innovation, commercial transformation, and M&A.Based on Zimmer Biomet…
Q2 net sales grew 4.8% year-over-year to $2.177 billion, with adjusted EPS steady at $2.07. Full-year 2026 revenue and adjusted EPS guidance were raised, reflecting strong performance and innovation momentum. Share repurchases and FDA clearances marked key developments.Original document: Zimmer Bio…
Zimmer Biomet reported second-quarter 2026 net sales of $2.177 billion, up 4.8% year-over-year (4.7% constant currency; 4.0% organic constant currency). GAAP diluted EPS was $1.03 and adjusted diluted EPS was $2.07, while net earnings were $198.3 million (adjusted net earnings $399.6 million). The…
Medical device company Zimmer Biomet NYSE:ZBHwill be announcing earnings results this Wednesday before market hours. Here’s what to look for.Zimmer Biomet beat analysts’ revenue expectations last quarter, reporting revenues of $2.09 billion, up 9.3% year on year. It was a strong quarter for the com…
Zimmer Biomet ZBH appears well positioned for growth in the coming quarters, supported by the continued execution of its market strategies centered on People and Culture, Operational Excellence, and Innovation and Diversification pillars. Growth in the knee business revenues is backed by the robust…
(17:18 GMT) Zimmer Biomet Holdings Price Target Cut to $110.00/Share From $120.00 by Evercore ISI Group
